At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 121 enrolled
Drug / intervention
avacincaptad pegol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease
In Brief
A Phase 2 clinical trial evaluating avacincaptad pegol and Sham for Stargardt's Macular Dystrophy. Completed, enrolled 121 participants across 41 sites in 8 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with autosomal recessive Stargardt disease 1 (STGD1).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStargardt's Macular Dystrophy
CountriesFrance, Germany, Hungary, Israel, Italy, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartJan 2018
Primary CompletionMar 2025
TodayJul 2026
First PostedDec 6, 2017
Enrollment StartJan 12, 2018
Primary CompletionMar 31, 2025
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 8.6 years ago
Interventions
avacincaptad pegoldrug
Intravitreal Injection
Shamdrug
Intravitreal Injection